July, 2024
July 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  
Alvaro Lassaletta: Promising results just published with MEMMAT in relapsed medulloblastoma
Oct 30, 2023, 18:52

Alvaro Lassaletta: Promising results just published with MEMMAT in relapsed medulloblastoma

Alvaro Lassaletta, Coordinator of the Brain Tumor Unit at Hospital Niño Jesús, shared a post on LinkedIn:

“Promising results just published with MEMMAT in relapsed medulloblastoma. Proud to have been part of this clinical trial. Thanks to El Sueño de Vicky for funding the trial in Spain.

Translation by LinkedIn-
Very promising results in children and adolescents with relapsed medulloblastoma with MEMMAT treatment. I am very proud that the Hospital Niño Jesús Brain Tumour Unit has participated in this international clinical trial. Impossible without funding from the El Sueño de Vicky foundation.

Thank you to all my colleagues in the Brain Tumours and Oncohaematology Unit, to the Clinical Trials Unit, to the FIB HNJS, to the SEHOP and to all the people who have made it possible, but above all thanks to the patients and their families because without their participation many other children and adolescents with Medulloblastoma would not have been able to benefit from this treatment.

Original post –
Resultados muy prometedores en niños y adolescentes con Meduloblastoma en recaída con tratamiento MEMMAT. Muy orgulloso de que la unidad de tumores cerebrales del Hospital Niño Jesús haya participado en este ensayo clínico internacional. Imposible sin la financiación de la fundación El Sueño de Vicky.

Gracias a todos mis compañeros de la unidad de tumores cerebrales y de Oncohematologia, a la unidad de ensayos clínicos, a la FIB HNJS, a la SEHOP y a todas las personas que lo han hecho posible, pero sobre todo gracias a los pacientes y a sus familias porque sin su participación muchos otros niños y adolescentes con Meduloblastoma no se hubieran podido beneficiar de este tratamiento.”

For more information click here.
Source: Alvaro Lassaletta/LinkedIn.